BioWorld：Inxmed raises $50M to develop cancer therapy in the US, China
2022-03-17 14:14
March 9, 2022
By Doris Yu
Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.
If you need more information, pls refer to the below link:
https://www.bioworld.com/articles/516796-inxmed-raises-50m-to-develop-cancer-therapy-in-the-us-china
Previous
None